A multicenter, open-label, prospective study of durvalumab, etoposide, and carboplatin for unresectable small cell lung cancer with mild idiopathic interstitial pneumonia - DREAM study A multicenter, open-label, prospective study of durvalumab, etoposide, and carboplatin for unresecta ...
Small cell lung cancer
Patients will receive etoposide (<75 years old: 100mg/m2; >=75 years old: 80mg/m2; intravenously on day 1-3), carboplatin (area under the curve 5 mg/mL intravenously on day 1), and durvalumab (1500mg/body intravenously on day1) every three weeks for four cycles. Thereafter, patients will continue to receive durvalumab monotherapy (1500mg/body intravenously on day 1 every three weeks), until relapse, or unacceptable toxicity. Patients will receive etoposide(<75 years old: 100mg/m2; >=75 years old: 80mg/m2; intravenously on d ...
A phase II Study of CBDCA + ETP + Nintedanib for SCLC with IPF
A Phase II Study of Carboplatin and Etoposide Plus Nintedanib for Unresectable Limited/Extensive Disease Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis - TORG1835 / NEXT-SHIP A Phase II Study of Carboplatin and EtoposidePlus Nintedanib for Unresectable Limited/Extensive Dise ...
Unresectable limited or extensive disease small cell lung cancer with idiopathic pulmonary fibrosis
The patients receive carboplatin(area under the curve 5 mg/mL, intravenously, day 1), etoposide (<75 years old:100mg/m2:>=75years old:80mg/m2;intravenously,days 1-3), and nintedanib (150mg twice a day, orally). The patients receive combination chemotherapy every3 weeks for 4 cycles until disease progression or unacceptable toxicity occurs. After completion or discontinuation of carboplatin plus etoposide, the patients continue nintedanib until the discontinuation criteria are satisfied. The patients receive carboplatin(area under the curve 5 mg/mL, intravenously, day 1), etoposide(<75 ...